At LSI 2021, Scott Huennekens, Chairman of the Board at Vida FLaSH Acquisitions sits down with Benjamin Glenn of A Matter of Innovation to discuss why this is the most exciting time in Medtech ever, what to do about those bumps in the road, the truth behind the magical journey of the unicorns and some advice on how to be a good leader, CEO or board member. This great discussion also covers the multi-tiered ecosystems that have emerged wherein apps, platforms, and data feed into a continuum of total care solutions, as well as the importance of bringing life-saving tech to the 7.5 billion people on the planet. AMOI Website
Benjamin Glenn is nationally recognized innovation strategist, speaker and coach based in the Silicon Valley. His work is keenly focused on helping entrepreneurs and innovators in enterprises big and small in our regulated industries identify, develop and maintain competitive advantages. Particularly with regard to our rapidly evolving health care sector, Benjamin's work is highlighted in Biodesign: The Process of Innovating Medical Technologies, a program he has served for over a decade.
Benjamin strongly believes in the increasing importance, and even the necessity, of creating and training a while array of multi-disciplinary teams. Benjamin's passionate presentations often focus on how professionals from different disciplines can successfully work together to create the products and services of the modern economy.
In his presentations, Benjamin draws on his diverse experiences growing up in Texas, serving in the military and working as a Silicon Valley patent attorney. His unique, humorous and often metaphor-ladened insights also draw from over two decades of advising clients on strategic, commercial, innovation and product development issues. As a result, his engaging style has inspired and entertained audiences at leading innovation and entrepreneurial programs nationwide including:
Stanford University BioDesign Program, UC San Francisco, Johns Hopkins University and Northwestern University, along with accelerator and incubator programs such as Matter Chicago, Texas Medical Center’s TMCx, South By SouthWest, VentureWell, Village Capital, Kauffman Foundation, Singularity University, and MedTech Innovator.
Benjamin Glenn is nationally recognized innovation strategist, speaker and coach based in the Silicon Valley. His work is keenly focused on helping entrepreneurs and innovators in enterprises big and small in our regulated industries identify, develop and maintain competitive advantages. Particularly with regard to our rapidly evolving health care sector, Benjamin's work is highlighted in Biodesign: The Process of Innovating Medical Technologies, a program he has served for over a decade.
Benjamin strongly believes in the increasing importance, and even the necessity, of creating and training a while array of multi-disciplinary teams. Benjamin's passionate presentations often focus on how professionals from different disciplines can successfully work together to create the products and services of the modern economy.
In his presentations, Benjamin draws on his diverse experiences growing up in Texas, serving in the military and working as a Silicon Valley patent attorney. His unique, humorous and often metaphor-ladened insights also draw from over two decades of advising clients on strategic, commercial, innovation and product development issues. As a result, his engaging style has inspired and entertained audiences at leading innovation and entrepreneurial programs nationwide including:
Stanford University BioDesign Program, UC San Francisco, Johns Hopkins University and Northwestern University, along with accelerator and incubator programs such as Matter Chicago, Texas Medical Center’s TMCx, South By SouthWest, VentureWell, Village Capital, Kauffman Foundation, Singularity University, and MedTech Innovator.
Scott is a successful Medtech CEO, Chairperson, board member, entrepreneur, and investor, having been involved in one of those roles in 20+ startup, growth and public companies with market valuations that have totaled over $20b and more importantly over 20 million patients that have benefited from the therapies and diagnostics of these companies. Current professional affiliations include Executive Chairperson Hyperfine (NASDAQ: HYPR) IPO 2021, Chairperson Acutus Medical (NASDAQ: AFIB) IPO 2020, Chairperson Envista (NYSE: NVST) IPO 2019, Board Member Nuvasive (NASDAQ: NUVA), Executive Chairperson & Investor Wondr Medical, Chairperson of the Board & Investor Kardion, Board member & Investor, Q’apel Medical, Board member & Investor Proximie, Board member Foldax, CEO Advisor & Investor Genesis Healthcare, Board Observer & Investor 270 Surgical, Board Member & past Chairperson Medical Device Manufacturer’s Association (MDMA), and advisor to Peloton Equity, 8VC, River Cities Capital and Accelmed Equity. He completed his role as Pres & CEO of Verb Surgical in early 2019. Verb was Google & J&J’s Surgical Robotics and Digital Surgery platform start-up to revolutionize the future of surgery which J&J acquired in 2019. Scott joined as employee #1. Previously, Scott led Volcano Corp. (NASDAQ: VOLC), a leader in minimally invasive therapy guidance in interventional cardiology, as its first & only Pres & CEO, from start-up in 2002 to its IPO in 2006 and sale to Philips in 2015. Volcano 2014 revenue was > $400 million and its market capitalization peaked at nearly $2B. Prior to this, he was at Digirad Corp, a diagnostic imaging solutions provider, from 1997 to 2002, as President & CEO. Digirad went public in 2004 (NASDAQ: DRAD). He graduated Magna Cum Laude with a BS in Bus Admin from the Univ. of Southern California in 1986 and earned his MBA from the Harvard Business School in 1991. Past affiliations include 12 other public and or VC funded medtech and biotech company boards of which 9 have had significant exits, including Chairperson of Endochoice (NYSE GI, acquired by Boston Scientific), Chairperson Sonendo (NYSE SONX IPO 2021), board member Vicarious Surgical (NYSE RBOT IPO 2021), board/CEO advisor Digital Surgery/Touch Surgery (Acquired by Medtronic). Scott has also been awarded E&Y’s entrepreneur of the year award in 2010 & was recognized by Goldman Sachs in 2016, 2017, & 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference.
Scott is a successful Medtech CEO, Chairperson, board member, entrepreneur, and investor, having been involved in one of those roles in 20+ startup, growth and public companies with market valuations that have totaled over $20b and more importantly over 20 million patients that have benefited from the therapies and diagnostics of these companies. Current professional affiliations include Executive Chairperson Hyperfine (NASDAQ: HYPR) IPO 2021, Chairperson Acutus Medical (NASDAQ: AFIB) IPO 2020, Chairperson Envista (NYSE: NVST) IPO 2019, Board Member Nuvasive (NASDAQ: NUVA), Executive Chairperson & Investor Wondr Medical, Chairperson of the Board & Investor Kardion, Board member & Investor, Q’apel Medical, Board member & Investor Proximie, Board member Foldax, CEO Advisor & Investor Genesis Healthcare, Board Observer & Investor 270 Surgical, Board Member & past Chairperson Medical Device Manufacturer’s Association (MDMA), and advisor to Peloton Equity, 8VC, River Cities Capital and Accelmed Equity. He completed his role as Pres & CEO of Verb Surgical in early 2019. Verb was Google & J&J’s Surgical Robotics and Digital Surgery platform start-up to revolutionize the future of surgery which J&J acquired in 2019. Scott joined as employee #1. Previously, Scott led Volcano Corp. (NASDAQ: VOLC), a leader in minimally invasive therapy guidance in interventional cardiology, as its first & only Pres & CEO, from start-up in 2002 to its IPO in 2006 and sale to Philips in 2015. Volcano 2014 revenue was > $400 million and its market capitalization peaked at nearly $2B. Prior to this, he was at Digirad Corp, a diagnostic imaging solutions provider, from 1997 to 2002, as President & CEO. Digirad went public in 2004 (NASDAQ: DRAD). He graduated Magna Cum Laude with a BS in Bus Admin from the Univ. of Southern California in 1986 and earned his MBA from the Harvard Business School in 1991. Past affiliations include 12 other public and or VC funded medtech and biotech company boards of which 9 have had significant exits, including Chairperson of Endochoice (NYSE GI, acquired by Boston Scientific), Chairperson Sonendo (NYSE SONX IPO 2021), board member Vicarious Surgical (NYSE RBOT IPO 2021), board/CEO advisor Digital Surgery/Touch Surgery (Acquired by Medtronic). Scott has also been awarded E&Y’s entrepreneur of the year award in 2010 & was recognized by Goldman Sachs in 2016, 2017, & 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference.
At LSI 2021, Scott Huennekens, Chairman of the Board at Vida FLaSH Acquisitions sits down with Benjamin Glenn of A Matter of Innovation to discuss why this is the most exciting time in Medtech ever, what to do about those bumps in the road, the truth behind the magical journey of the unicorns and some advice on how to be a good leader, CEO or board member. This great discussion also covers the multi-tiered ecosystems that have emerged wherein apps, platforms, and data feed into a continuum of total care solutions, as well as the importance of bringing life-saving tech to the 7.5 billion people on the planet. AMOI Website
Market Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy